Make your money go further for just 25p per day

Bioventix (AIM:BVXP) record results from this unusual high margin offering

05/10/2015 · Bioventix PLC (BVXP) 

The developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, announced fantastic audited results for the year ended 30 June 2015. Pre-tax margins of over 70% and superb cash generation highlight the unusual (yet highly attractive) nature of this small business

We published a detailed commentary on this back in April 2015 which is worth a read.

For the year to 30th June 2015 revenue was up 23% to £4.3m and pre-tax profit up 39% to £3.1m (2013/14: £2.2m). The operating cash inflow was also a majestic £2.915m with free cash flow £2m after a modest £113k of capex. Year-end cash was £4.13m after the payment of equity…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login

Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world


Become a Champion Investor for just £90 a year.


More on Bioventix PLC

Coronavirus impact: 30 March - a hint of resilience

30/03/2020 · Company Insights

The week has started with yet more dividend postponements and cancellations but also some fabulous results…

Champion Chatter – what costs more than £500,000 per gram?

08/10/2018 · Company Insights
News today includes fantastic results from a highly unusual small cap and a cracking load of…

More Company Insights

Is Rishi going to keep hospitality alive?

10/07/2020 · JD Wetherspoon · Young & Co.

Coronavirus impact: 10 July - a home recording lockdown winner

If Huawei is unravelled can BT and Vodafone pay their dividends?

10/07/2020 · BT · Vodafone